268 related articles for article (PubMed ID: 23927080)
1. Vascular endothelial growth factor gene polymorphism prevalence in patients with diabetic macular oedema and its correlation with anti-vascular endothelial growth factor treatment outcomes.
El-Shazly SF; El-Bradey MH; Tameesh MK
Clin Exp Ophthalmol; 2014; 42(4):369-78. PubMed ID: 23927080
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema.
Sheth S; Rush R; Natarajan S; Gillies M
Clin Exp Ophthalmol; 2011; 39(7):673-81. PubMed ID: 22452685
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of intravitreal bevacizumab on diabetic macular oedema in an African population.
Kyei S; Asare FA; Assan JK; Zaabaar E; Assiamah F; Obeng EO; Asiedu K
Ir J Med Sci; 2023 Dec; 192(6):2777-2783. PubMed ID: 36988835
[TBL] [Abstract][Full Text] [Related]
4. Visual outcome after intravitreal bevacizumab depends on the optical coherence tomographic patterns of patients with diffuse diabetic macular edema.
Shimura M; Yasuda K; Yasuda M; Nakazawa T
Retina; 2013 Apr; 33(4):740-7. PubMed ID: 23222391
[TBL] [Abstract][Full Text] [Related]
5. VEGF-A gene polymorphisms and responses to intravitreal ranibizumab treatment in patients with diabetic macular edema.
Tetikoğlu M; Yüksel Z; Aktas S; Sağdik HM; Özcura F
Int Ophthalmol; 2018 Dec; 38(6):2381-2388. PubMed ID: 29030794
[TBL] [Abstract][Full Text] [Related]
6. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment.
Reznicek L; Cserhati S; Seidensticker F; Liegl R; Kampik A; Ulbig M; Neubauer AS; Kernt M
Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578
[TBL] [Abstract][Full Text] [Related]
7. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
9. Anti-vascular endothelial growth factor for diabetic macular oedema.
Virgili G; Parravano M; Menchini F; Evans JR
Cochrane Database Syst Rev; 2014 Oct; (10):CD007419. PubMed ID: 25342124
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.
Parravano M; Menchini F; Virgili G
Cochrane Database Syst Rev; 2009 Oct; (4):CD007419. PubMed ID: 19821414
[TBL] [Abstract][Full Text] [Related]
11. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab (Avastin) for primary treatment of diabetic macular oedema.
Ozkiriş A
Eye (Lond); 2009 Mar; 23(3):616-20. PubMed ID: 18437176
[TBL] [Abstract][Full Text] [Related]
13. Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.
Mehta H; Hennings C; Gillies MC; Nguyen V; Campain A; Fraser-Bell S
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011599. PubMed ID: 29669176
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal aflibercept for diabetic macular oedema: Moorfields' real-world 12-month visual acuity and anatomical outcomes.
Lukic M; Williams G; Shalchi Z; Sim D; Patel PJ; Keane PA; Hykin PG; Sivaprasad S; Menon D; Bruynseels A; Hamilton RD; Rajendram R
Eur J Ophthalmol; 2020 May; 30(3):557-562. PubMed ID: 30808179
[TBL] [Abstract][Full Text] [Related]
15. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema.
Nepomuceno AB; Takaki E; Paes de Almeida FP; Peroni R; Cardillo JA; Siqueira RC; Scott IU; Messias A; Jorge R
Am J Ophthalmol; 2013 Sep; 156(3):502-510.e2. PubMed ID: 23795985
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.
Virgili G; Parravano M; Menchini F; Brunetti M
Cochrane Database Syst Rev; 2012 Dec; 12():CD007419. PubMed ID: 23235642
[TBL] [Abstract][Full Text] [Related]
17. Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
Jampol LM; Glassman AR; Liu D; Aiello LP; Bressler NM; Duh EJ; Quaggin S; Wells JA; Wykoff CC;
Ophthalmology; 2018 Jul; 125(7):1054-1063. PubMed ID: 29525602
[TBL] [Abstract][Full Text] [Related]
18. Gender-related differences in patients treated with intravitreal anti-vascular endothelial growth factor medication for diabetic macular oedema.
Schiefelbein J; Müller M; Kern C; Herold T; Liegl R; Fasler K; Jeliazkova D; Priglinger S; Kortuem KU
Eur J Ophthalmol; 2020 Nov; 30(6):1410-1417. PubMed ID: 31937122
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population.
Kumar A; Sinha S
Indian J Ophthalmol; 2007; 55(6):451-5. PubMed ID: 17951903
[TBL] [Abstract][Full Text] [Related]
20. Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in type 2 diabetes.
Awata T; Kurihara S; Takata N; Neda T; Iizuka H; Ohkubo T; Osaki M; Watanabe M; Nakashima Y; Inukai K; Inoue I; Kawasaki I; Mori K; Yoneya S; Katayama S
Biochem Biophys Res Commun; 2005 Aug; 333(3):679-85. PubMed ID: 15963467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
